Michael T. Hemann

Michael T. Hemann

Professor of Biology; Intramural Faculty, Koch Institute

Michael T. Hemann uses mouse models to combat cancers resistant to chemotherapy.

617-324-1964

Phone

76-361

Office

hemann@mit.edu

Email

Koch Institute for Integrative Cancer Research

Location

Lab Website
Ryan Hayman

Assistant

617-253-0796

Assistant Phone

Education

  • PhD, 2001, Johns Hopkins University
  • BS, 1993, Molecular Biology and Biochemistry, Wesleyan University

Research Summary

Many human cancers do not respond to chemotherapy, and often times those that initially respond eventually acquire drug resistance. Our lab uses high-throughput screening technology — combined with murine stem reconstitution and tumor transplantation systems — to investigate the genetic basis for this resistance. Our goal is to identify novel cancer drug targets, as well as strategies for tailoring existing cancer therapies to target the vulnerabilities associated with specific malignancies.

Key Publications

  1. Integrated regulatory models for inference of subtype-specific susceptibilities in glioblastoma. Liu, Y, Shi, N, Regev, A, He, S, Hemann, MT. 2020. Mol Syst Biol 16, e9506.
    doi: 10.15252/msb.20209506PMID:32974985
  2. Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance. Dalin, S, Sullivan, MR, Lau, AN, Grauman-Boss, B, Mueller, HS, Kreidl, E, Fenoglio, S, Luengo, A, Lees, JA, Vander Heiden, MG et al.. 2019. Cancer Res 79, 5723-5733.
    doi: 10.1158/0008-5472.CAN-19-0960PMID:31484670
  3. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Bruno, PM, Liu, Y, Park, GY, Murai, J, Koch, CE, Eisen, TJ, Pritchard, JR, Pommier, Y, Lippard, SJ, Hemann, MT et al.. 2017. Nat Med 23, 461-471.
    doi: 10.1038/nm.4291PMID:28263311
  4. Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution. Zhao, B, Sedlak, JC, Srinivas, R, Creixell, P, Pritchard, JR, Tidor, B, Lauffenburger, DA, Hemann, MT. 2016. Cell 165, 234-246.
    doi: 10.1016/j.cell.2016.01.045PMID:26924578
  5. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Pallasch, CP, Leskov, I, Braun, CJ, Vorholt, D, Drake, A, Soto-Feliciano, YM, Bent, EH, Schwamb, J, Iliopoulou, B, Kutsch, N et al.. 2014. Cell 156, 590-602.
    doi: 10.1016/j.cell.2013.12.041PMID:24485462

Recent Publications

  1. Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening. Ramos, A, Koch, CE, Liu-Lupo, Y, Hellinger, RD, Kyung, T, Abbott, KL, Fröse, J, Goulet, D, Gordon, KS, Eidell, KP et al.. 2023. Nat Commun 14, 8048.
    doi: 10.1038/s41467-023-43790-2PMID:38052854
  2. Integrated multi-omics analyses reveal homology-directed repair pathway as a unique dependency in near-haploid leukemia. Liu-Lupo, Y, Ham, JD, Jeewajee, SKA, Nguyen, L, Delorey, T, Ramos, A, Weinstock, DM, Regev, A, Hemann, MT. 2023. Blood Cancer J 13, 92.
    doi: 10.1038/s41408-023-00863-1PMID:37286545
  3. Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse. Dalin, S, Grauman-Boss, B, Lauffenburger, DA, Hemann, MT. 2022. Sci Rep 12, 5453.
    doi: 10.1038/s41598-022-09319-1PMID:35361803
  4. Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy. Bent, EH, Millán-Barea, LR, Zhuang, I, Goulet, DR, Fröse, J, Hemann, MT. 2021. Nat Commun 12, 6218.
    doi: 10.1038/s41467-021-26407-4PMID:34711820
  5. Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer. Vassel, FM, Bian, K, Walker, GC, Hemann, MT. 2020. Proc Natl Acad Sci U S A 117, 28922-28924.
    doi: 10.1073/pnas.2016067117PMID:33144509
  6. Integrated regulatory models for inference of subtype-specific susceptibilities in glioblastoma. Liu, Y, Shi, N, Regev, A, He, S, Hemann, MT. 2020. Mol Syst Biol 16, e9506.
    doi: 10.15252/msb.20209506PMID:32974985
  7. Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance. Dalin, S, Sullivan, MR, Lau, AN, Grauman-Boss, B, Mueller, HS, Kreidl, E, Fenoglio, S, Luengo, A, Lees, JA, Vander Heiden, MG et al.. 2019. Cancer Res 79, 5723-5733.
    doi: 10.1158/0008-5472.CAN-19-0960PMID:31484670
  8. Functional screens identify coordinators of RNA molecule birth, life, and death as targetable cancer vulnerabilities. Braun, CJ, Hemann, MT. 2019. Curr Opin Genet Dev 54, 105-109.
    doi: 10.1016/j.gde.2019.04.003PMID:31121413
  9. In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1+ BCP-ALL. Fiedler, ERC, Bhutkar, A, Lawler, E, Besada, R, Hemann, MT. 2018. Blood Adv 2, 1229-1242.
    doi: 10.1182/bloodadvances.2017015610PMID:29853524
  10. Drugs, Bugs, and Cancer: Fusobacterium nucleatum Promotes Chemoresistance in Colorectal Cancer. Ramos, A, Hemann, MT. 2017. Cell 170, 411-413.
    doi: 10.1016/j.cell.2017.07.018PMID:28753421
More Publications

Multimedia

Photo credit: Bryce Vickmark